<DOC>
	<DOC>NCT00504842</DOC>
	<brief_summary>This is a randomized, placebo controlled, parallel group dose escalation trial to evaluate the safety, tolerability, and activity of four sequential dose tiers of MRX-801 and ultrasound as an adjunctive therapy to tissue plasminogen activator (tPA) treatment in subjects with acute ischemic stroke.</brief_summary>
	<brief_title>Transcranial Ultrasound in Clinical SONothrombolysis</brief_title>
	<detailed_description />
	<mesh_term>Stroke</mesh_term>
	<mesh_term>Ischemia</mesh_term>
	<mesh_term>Cerebral Infarction</mesh_term>
	<mesh_term>Tissue Plasminogen Activator</mesh_term>
	<criteria>Acute ischemic stroke Occlusion demonstrated by transcranial Doppler ultrasound Eligible for tPA Right to left cardiac shunt Moderate to severe COPD Uncontrolled hypertension</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2008</verification_date>
	<keyword>Acute Ischemic Stroke</keyword>
	<keyword>Microbubbles</keyword>
	<keyword>Transcranial Doppler ultrasound</keyword>
	<keyword>TIBI</keyword>
	<keyword>Symptomatic Intracranial Hemorrhage</keyword>
	<keyword>modified Rankin Scale</keyword>
	<keyword>Recanalization</keyword>
	<keyword>Perflutren</keyword>
</DOC>